Antibody Combinations Targeting the Essential Antigens CyRPA, RH5, and MSP-119 Potently Neutralize P
Updated: May 3, 2021
Hina Singh, Syed Yusuf Mian, Alok K Pandey, Sri Krishna, Gaurav Anand, K Sony Reddy, Neha Chaturvedi, Vanndita Bahl, Nidhi Hans, Man Mohan Shukla, Quique Bassat, Alfredo Mayor, Kazutoyo Miura, Praveen K Bharti, Carole Long, Neeru Singh, Virander Singh Chauhan, Deepak Gaur
Targeting multiple key antigens that mediate distinct Plasmodium falciparum erythrocyte invasion pathways is an attractive approach for the development of blood-stage malaria vaccines. However, the challenge is to identify antigen cocktails that elicit potent strain-transcending parasite-neutralizing antibodies efficacious at low immunoglobulin G concentrations feasible to achieve through vaccination. Previous reports have screened inhibitory antibodies primarily against well adapted laboratory parasite clones. However, validation of the parasite-neutralizing efficacy against clinical isolates with minimal in vitro cultivation is equally significant to better ascertain their prospective in vivo potency.